Jagsonpal Pharmaceuticals Ltd. experienced a significant rally on Tuesday, with its stock price jumping 14.44% to reach a day high of Rs 264.65. The surge came after the small-cap pharma company announced its strategic acquisition of an 85% stake in Aequitas Healthcare, a Mumbai-based firm, signaling Jagsonpal's entry into the burgeoning hospital segment.
Strategic Expansion into India's Healthcare Ecosystem
The acquisition of Aequitas Healthcare is a pivotal move for Jagsonpal, aligning with its long-term vision to bolster its presence within India's expanding healthcare landscape. According to the company, this transaction represents a transformative shift from its traditional retail prescription focus to an omnichannel specialty healthcare business.
Founded in 2017, Aequitas Healthcare has established a strong business, serving all major hospital chains across India. In the fiscal year 2026, Aequitas reported revenues of Rs 53 crore.
Acquisition Details and Funding
Jagsonpal Pharmaceuticals will acquire the 85% stake in Aequitas Healthcare for a total consideration of Rs 20.8 crore. This acquisition will be funded entirely through Jagsonpal's internal accruals. The current directors of Aequitas will retain the remaining 15% stake and will continue their association with the business to ensure continuity and leverage their expertise. The transaction is subject to standard closing conditions and is anticipated to conclude by July 15, 2026.
Operational Transformation and Market Outlook
Amrut Medhekar, Chief Operating Officer at Jagsonpal, emphasized the transformative nature of the deal. He stated, “This transaction is a structurally transformative pivot that moves Jagsonpal from a legacy retail prescription player to Omnichannel Specialty healthcare business in India and is reflective of our long-term commitment to building scalable, high-quality healthcare delivery in India.” Medhekar expressed optimism about unlocking value through operational excellence, disciplined execution, and patient-centric growth.
Market analysts have offered cautious advice following the sharp rise. Ravi Singh, Chief Research Officer at Master Capital Services, suggested that some short-term profit booking might occur. He advised traders to consider booking partial profits and trailing stop-losses to protect gains, while long-term investors might consider holding or accumulating on dips rather than chasing the current rally.